For a short update in Norwegian on the recent results in melanoma and mesothelioma, please see video below (from DNB Markets):
CAPITAL MARKETS DAY
With strong clinical data generated on ONCOS-102, Targovax is moving into late-stage clinical development. In addition, a broad pipeline of preclinical assets creates a broad horizon of opportunities in the future. See the replay of our Capital Markets Day in the link below.
Targovax ASA announced its first quarter 2021 results on Thursday 6 May 2021. An online presentation by Targovax’s management to investors, analysts and the press took place the same day at 10:00 am CEST.
Our strategy
Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
Targovax has built on the previous immune activation and anti-tumor findings and showed that the combination of ONCOS-102 and Keytruda can generate systemic responses that reduce the size of non-injected lesions, i.e. abscopal anti-tumor effect. This work was performed in a humanized melanoma mouse model with tumors inoculated dorsally on both sides of the animals. After the tumors were established, ONCOS-102 was injected directly into the tumor on one side only, followed by systemic treatment with Keytruda. By Day 40, tumors on the non-injected side of the animals had shrunk by an average of 70%.
Targovax is developing a cancer immunotherapeutic technology with a targeted mechanism of action, making tumors visible to the immune system and educating the immune system to recognize and attack patient specific tumor cells. The technology is based on adenoviruses engineered to kill tumor cells primarily via activation of a systemic, patient-specific anti-tumor immune response. The lead clinical candidate is ONCOS-102.
Peptide-based neoantigencancer vaccines activate cancer specific T – cell immune-responses. Mutant RAS proteins are neoantigen and drivers for development of cancer. RAS mutations are exclusively found in cancer cells and are therefore cancer specific targets for attacking cancer immunologically.